Unlocking Opportunities in the Preeclampsia Drugs Market: Key Growth Trends and Forecast Insights
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Factors Are Driving the Anticipated Growth Rate of the Preeclampsia Drugs Market Through 2034?
There has been a swift expansion in the market size for preeclampsia drugs in the past few years. The current value of $1.25 billion in 2024 is projected to climb to $1.38 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this rise during the historical period include heightened awareness around maternal health, strides made in research and development, concerns regarding neonatal health, and improved early detection methods.
Anticipated to witness swift expansion in the coming years, the market size of preeclampsia drugs is projected to elevate to $2.12 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. Factors contributing to the growth, during the predicted period consist of personalized medications, non-invasive diagnostic devices, targeted treatments, and initiatives for health equality. Preventive measures, patient-focused care, ongoing monitoring, and regulatory attention are amongst the major trends during the forecast period.
What Drivers Are Shaping the Growth of the Preeclampsia Drugs Market?
The upward trend in diabetes among expectant mothers is predicted to fuel the expansion of the preeclampsia drug market. A metabolic disorder, diabetes, is a long-term illness characterized by elevated levels of blood glucose or sugar. Preeclampsia is a harmful pregnancy condition with increased blood pressure and organ damage. Metformin, a preeclampsia medicine, is commonly used in pregnant women with early onset preeclampsia. For instance, the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, reported in December 2022 that the total incidence of gestational diabetes mellitus (GDM) was 20,865 cases, representing a 6.56% increase in 2022. Hence, the increasing incidence of diabetes among pregnant women will bolster the preeclampsia drug market. The swelling prevalence of lifestyle-related illnesses is anticipated to drive the growth of the preeclampsia drugs market. Lifestyle diseases, also known as non-communicable diseases (NCDs), are principally caused by unhealthy lifestyle choices and behaviors. These diseases, which include hypertension, obesity, and diabetes, are risk factors for preeclampsia and thus treated with preeclampsia drugs. According to the World Health Organization, a Switzerland-based specialized agency of the United Nations, in September 2022, there were 41 million deaths, which accounts for 74% of the total fatalities caused by NCDs or chronic diseases every year worldwide. These figures included 17.9 million deaths from cardiovascular illnesses, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Thus, the escalating prevalence of lifestyle diseases drives the expansion of the preeclampsia drugs market.
Get Your Free Sample of the Global Preeclampsia Drugs Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp
Who Are the Major Industry Leaders Accelerating Growth in the Preeclampsia Drugs Market?
Major companies operating in the preeclampsia drugs market are:
• AbbVie Inc._x000D_
• Pfizer Inc._x000D_
• Johnson & Johnson Co_x000D_
• F. Hoffmann-La Roche Ltd._x000D_
• Merck & Co. Inc._x000D_
Which Current Trends Are Having the Most Impact on the Preeclampsia Drugs Market?
In an effort to strengthen their hold on the preeclampsia medicine market, leading companies are concentrating on creating innovative drug solutions. To illustrate, Comanche Biopharma Corp., a biopharmaceutical company based in the US, announced in March 2023 that the Food and Drug Administration (FDA) gave approval to a new investigational drug (IND) application for CBP-4888. This is Comanche’s unique siRNA treatment for preeclampsia. Administered subcutaneously, CBP-4888 is a siRNA therapy that mitigates the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The main reason for preeclampsia is the excess production of the protein sFLT1 in the placenta that then makes its way into the mother’s circulation. Symptoms of preeclampsia such as elevated blood pressure and organ damage can be alleviated by CBP-4888, potentially enabling a safe prolongation of pregnancy.
Get Instant Access to the Global Preeclampsia Drugs Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
What Are the Major Categories and Their Growth Dynamics in the Preeclampsia Drugs Market?
The preeclampsia drugs market covered in this report is segmented –
1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management
Which Regions Are Key Players in the Growth of the Preeclampsia Drugs Market?
North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Elements Shape the Definition of the Preeclampsia Drugs Market?
Preeclampsia drugs refer to medications that manage and treat the condition of pre-eclampsia, a serious pregnancy complication characterized by high blood pressure and damage to organs such as the liver and kidneys. These drugs are typically prescribed by healthcare professionals to pregnant women diagnosed with preeclampsia to help lower blood pressure and prevent further complications.
Browse Through More Similar Reports By The Business Research Company:
Female Fertility And Pregnancy Rapid Test Global Market Report 2024
Fertility Treatments Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report
Hormonal Contraceptives Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
